Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02967250|
Recruitment Status : Completed
First Posted : November 18, 2016
Last Update Posted : March 22, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Parkinson Disease||Drug: ursodeoxycholic acid||Phase 1|
The objective of this study is to understand the bioenergetic impairments that underlie Parkinson's disease (PD) and evaluating treatments that may improve abnormal mitochondrial function that is present in PD. High field - 7 tesla (T) - magnetic resonance spectroscopy (MRS) is able to non-invasively assess for changes in brain energetics and will be used to evaluate the effects that repeated oral doses of the mitochondrial enhancer ursodeoxycholic acid (UDCA) has on brain bioenergetics derived from MRS measurements. This study will combine results obtained using MRS brain scans along with peripheral measurements of bile acids (e.g., total UDCA). This research will require at least 2 visits: baseline evaluation and at approximately 6 weeks after subjects are on a stable oral dose for 4 weeks. Participants will provide their medical history during the first visit, and undergo a physical examination and rating scale each visit (duration: ~1 hour) as well as a brain MRI scan (1-1.5 hours). Blood will be obtained at both visits to monitor for adverse effects as well as to assess for changes in bile acids from orally administered UDCA. If additional funding is obtained we may have another visit added between the first and second assessments to obtain additional blood measurements and MRS data.
Since there is extensive animal and cell model data supporting the rationale for a therapeutic trial of UDCA in PD, and because MRS methods can non-invasively detect changes in brain chemistry we propose a study to evaluate the effects of a 4-6 weeks of high-dose oral UDCA on central (brain) and peripheral measures (through MRS and blood measurements, respectively) in individuals with PD and healthy controls. The hypothesis and specific aims are as follows:
Hypothesis: Repeated oral dosing of UDCA will result in increased brain ATP levels in individuals with Parkinson's disease (PD).
- Measure plasma UDCA levels in individuals with PD at baseline and after four weeks of repeated high doses of oral UDCA (50mg/kg/day).
- Measure cortical bioenergetic profile and ATPase activity (as ascertained through MRS) in those with PD at baseline and at four weeks after repeated high doses of oral UDCA (50mg/kg/day) simultaneously with Aim 1.
- Characterize oral UDCA pharmacokinetics
- Develop a pharmacokinetic/pharmacodynamic model to characterize the relationship between peripheral measurements of UDCA (and associated conjugates) and peripheral measures and/or central (brain) bioenergetic measurements.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||5 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||7T Magnetic Resonance Spectroscopy Monitoring Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment|
|Actual Study Start Date :||April 1, 2020|
|Actual Primary Completion Date :||February 28, 2022|
|Actual Study Completion Date :||February 28, 2022|
Experimental: Ursodeoxycholic acid treatment
Each subject will receive UDCA intervention for six weeks.
Drug: ursodeoxycholic acid
Subjects will be provided ~50mg/kg/day (based on the use of 250 and 500mg capsules) of UDCA to be divided into 3 equal daily doses and titrated up over ~2 weeks to a stable dose for 4 weeks.
Other Name: Ursodiol
- Change in ATP concentration [ Time Frame: prior to intervention and at 6 weeks of intervention ]measurement of ATP concentrations in brain using 7T MRS
- UDCA pharmacokinetics [ Time Frame: at 6 weeks of intervention ]measurement of UDCA concentration in plasma will be used to determine pharmacokinetics
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- All participants must be 18 years or older.
- All enrollees must understand and cooperate with requirements of the study and be able to provide written informed consent
- Individuals with medically stable mild to moderate Parkinson's disease or healthy controls (as determined by enrolling investigator)
- All participants must not have taken UDCA for 4 weeks prior to the study.
- Absence of dementia in all subjects, as determined by pre-scanning cognitive assessment.
- Inability to undergo MRI scanning without sedation and other MRI counterindications, such as metal in the body.
- Medically unstable conditions
- Pregnant or lactating or those women of child-bearing age that are not using acceptable forms of contraception
- Unable to adhere to study protocol as determined by the PI
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02967250
|United States, Minnesota|
|Center for Magnetic Resonance Research|
|Minneapolis, Minnesota, United States, 55455|
|Principal Investigator:||Lisa Coles, PhD||University of Minnesota|
|Principal Investigator:||Paul Tuite, MD||University of Minnesota|
|Responsible Party:||University of Minnesota|
|Other Study ID Numbers:||
|First Posted:||November 18, 2016 Key Record Dates|
|Last Update Posted:||March 22, 2022|
|Last Verified:||March 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Basal Ganglia Diseases
Central Nervous System Diseases
Nervous System Diseases
Cholagogues and Choleretics